Glycogen storage disease type II cost-effectiveness of therapy
Glycogen storage disease type II Microchapters |
Differentiating Glycogen storage disease type II from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type II cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type II cost-effectiveness of therapy |
FDA on Glycogen storage disease type II cost-effectiveness of therapy |
CDC on Glycogen storage disease type II cost-effectiveness of therapy |
Glycogen storage disease type II cost-effectiveness of therapy in the news |
Blogs on Glycogen storage disease type II cost-effectiveness of therapy |
Directions to Hospitals Treating Glycogen storage disease type II |
Risk calculators and risk factors for Glycogen storage disease type II cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Cost-Effectiveness of Therapy
Myozyme costs an average of $300,000 a year, and must be taken for the patients' entire life. Some insurers have refused to pay for it.[1].
References
- ↑ Burden of Proof: As Costs Rise, New Medicines Face Pushback; Insurers Limit Coverage To FDA-Approved Uses; $300,000 Drug Denied By GEETA ANAND, Wall Street Journal, September 18, 2007